Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Angiogenesis in hematologic malignancies.

T M Moehler1, K Neben, A D Ho

  • 1Department of Internal Medicine V, University of Heidelberg, Hospitalstrasse 3, 69115 Heidelberg, Germany, Thomas_Moehler@med.uni-heidelberg.de

Annals of Hematology
|January 18, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Same author

An automated approach to determine antibody endpoint titers for COVID-19 by an enzyme-linked immunosorbent assay.

Immunohematology·2021
Same author

Transplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD.

Bone marrow transplantation·2017
Same author

Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma.

BMC cancer·2017
Same author

Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation.

Oncogenesis·2017
Same author

GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses.

Bone marrow transplantation·2017
Same journal

Transcriptomic profiling of an in vivo diffuse large B-cell lymphoma model reveals molecular programs underlying CNS dissemination.

Annals of hematology·2026
Same journal

A systematic review of 47 published cases of extramedullary hematopoiesis in myelofibrosis: clinical patterns, treatment responses, and prognostic implications.

Annals of hematology·2026
Same journal

A case report of CD4<sup>-</sup> CD8<sup>+</sup> CD56<sup>-</sup> TCRγδ<sup>+</sup> T-large granular lymphocytic leukaemia with severe aplastic anemia and a PNH clone.

Annals of hematology·2026
Same journal

An assessment of the effectiveness of hydroxyurea therapy in children and adolescents with sickle cell anaemia at Kenyatta National Hospital.

Annals of hematology·2026
Same journal

Allogeneic hematopoietic stem cell transplantation for a pediatric case of myelodysplastic syndrome with germline DDX41 mutation.

Annals of hematology·2026
Same journal

Clinical and prognostic significance of concomitant autoimmune disease in patients with myelofibrosis.

Annals of hematology·2026
See all related articles

Angiogenesis, the formation of new blood vessels, is crucial in solid tumor growth and is now recognized in blood cancers. Antiangiogenic therapies, inspired by treatments for multiple myeloma, are being explored for various hematologic neoplasms.

Area of Science:

  • Oncology
  • Hematology
  • Vascular Biology

Background:

  • Angiogenesis, the generation of new blood vessels from existing ones, is vital for solid tumor progression.
  • Bone marrow-derived endothelial precursor cells may contribute to tumor angiogenesis.
  • Angiogenesis induction is observed in hematologic neoplasms like leukemia, lymphoma, myelodysplastic syndrome, and multiple myeloma (MM).

Purpose of the Study:

  • To review the role of angiogenesis in hematologic neoplasms.
  • To highlight the clinical relevance of angiogenesis markers (angiodiagnosis).
  • To discuss the development of antiangiogenic treatments for these cancers.

Main Methods:

  • Review of clinical angiogenesis research and angiodiagnosis.
  • Examination of prognostic markers like microvessel density and circulating angiogenic peptides.

Related Experiment Videos

  • Analysis of antiangiogenic treatment strategies, including Thalidomide (Thal) in MM.

    • Main Results:

    • Angiogenesis plays a significant role in the progression of solid tumors and is implicated in hematologic neoplasms.
    • Clinical angiogenesis research has established the prognostic value of specific markers.
    • Thalidomide's success in multiple myeloma has spurred the development of antiangiogenic therapies for hematologic malignancies.

    Conclusions:

    • Angiogenesis is a key factor in both solid tumors and hematologic neoplasms.
    • Antiangiogenic therapies show promise and are under investigation for various blood cancers.
    • Further research into antiangiogenic treatments is warranted for hematologic malignancies.